Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers September 27, 2016
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - September 27, 2016

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

9/27/16 - 11 ASX Pharmaceutical Stocks: An Investor's Introduction
Investing in foreign stock markets can be intimidating. Here at Life Science Investing News, we want to make the process a little easier. Acrux has also returned $1.02/ share via dividend to investors over the past 5 years.
9/27/16 - 4 Pharma coys get WHO recognition, 16 under consideration
Four pharmaceutical companies in Nigeria have been awarded on Monday with the World Health Organization pre-qualified certificates for production of drugs. The companies are May and Maker, Evans, Swipha and CHI Pharmaceuticals while sixteen are under serious consideration. Yakasai disclosed this when he led a team of Pharmaceutical Industry Sector
9/27/16 - Abiomed Impella 2.5?and Impella 5.0? Heart Pumps Receive Regulatory Approval From Japan Ministry of Health, Labor & Welfare
Abiomed, Inc., a leading provider of breakthrough heart support technologies, announced today that the Impella 2.5 and Impella 5.0 heart pumps received Pharmaceuticals and Medical Devices Agency approval from the Japanese Ministry of Health, Labor& Welfare for the treatment of drug-resistant acute heart failure.. With this approval, these are the
9/27/16 - Acceleron Announces Retirement of John Knopf as President and CEO; Habib Dable Named as Successor
Acceleron Pharma Inc., a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced the Company has appointed Habib Dable as President and Chief Executive Officer to succeed current President and CEO John Knopf.
9/27/16 - AcelRx Initiates Phase 3 Study of Zalviso in Patients with Moderate-to-Severe Acute Post-Operative Pain
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced today the initiation of the Phase 3 IAP312 study of Zalviso , an investigational product candidate being developed for the management of...
9/27/16 - Achaogen Announces New Employment Inducement Grants
Achaogen, Inc., a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant gram-negative infections, today announced that on September 23, 2016, the compensation committee of the Company's board of directors granted six new employees options to purchase an aggregate of 72,750 shares of the Company's
9/27/16 - Actinium Announces Initiation of Phase 2 Clinical Trial of Actimab-A in Patients Newly Diagnosed with Acute Myeloid Leukemia Over Age 60
Actinium Pharmaceuticals, Inc., a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that the Company has initiated a Phase 2 clinical trial of Actimab-A in patients newly diagnosed with Acute Myeloid Leukemia who are over the age of 60. Actimab-A, Actinium's
9/27/16 - Actinium Pharmaceuticals to Sponsor and Participate in Be The Match Walk+Run to Raise Awareness for Bone Marrow Transplant [Daily Star, The (Lebanon)]
-Actinium Pharmaceuticals, Inc., a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that the Company has sponsored and will participate in the upcoming Be The Match Walk+ Run being held on Saturday, October 1, 2016, at Firefighters Field on Roosevelt Island, N
9/27/16 - AHN doctors, patients to have role in diabetic device development [Pittsburgh Post-Gazette]
Sept. 27 People with diabetes could soon get more help managing the disease, thanks to a $500 million joint venture involving Allegheny Health Network, drugmaker Sanofi and Verily Life Sciences LLC, a unit of Google parent Alphabet. French pharmaceutical giant Sanofi partnered with software and miniature electronics company Verily of Mountain Vie
9/27/16 - Allergan to Present New Data at the American Urogynecologic Society Annual Meeting in Denver
Allergan plc, a leading global pharmaceutical company today announced that it has presentations in overactive bladder and nocturia at the upcoming American Urogynecologic Society Annual Scientific Meeting in Denver, Colorado, September 27- October 1. Allergan plc, headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a le
9/27/16 - ANI Pharmaceuticals Announces Launch of Erythromycin Ethylsuccinate for Oral Suspension, 200mg/5mL
ANI Pharmaceuticals, Inc. today announced the launch of Erythromycin Ethylsuccinate for Oral Suspension 200 mg/5mL indicated as a treatment for various infections. Arthur S. Przybyl, ANI's President and CEO stated, "This is the first product that we are launching from the basket of 22 previously marketed generic products that we acquired in July
9/27/16 - Ansun BioPharma Announces Two Publications Showing Inhibitory Effects of DAS181 on Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV)
Ansun BioPharma announced today the publication of two reports by researchers showing potent inhibitory effect of DAS181 on respiratory syncytial virus and human metapneumovirus. "DAS181 Blocks Respiratory Syncytia Virus Infection of Hep-2 Cells" was published in the peer reviewed Journal of Antivirals& Antiretrovirals was published by Dr.
9/27/16 - Apotex Ofloxacin Otic Solution 0.3% Generic Version of Floxin Otic Now Available
Apotex Inc. is the 7th largest generic pharmaceutical company globally with over 10,500 employees and estimated sales of approximately $2 billion. The company's US headquarters is based in Weston, Florida. The majority of Apotex sites, including manufacturing, are in North America.
9/27/16 - ARK Animal Health, a Subsidiary of Sorrento Therapeutics, Announces Submission of Two Major Technical Sections of a New Animal Drug Application
ARK Animal Health, Inc., a subsidiary of Sorrento Therapeutics, Inc., has filed the Effectiveness and Target Animal Safety major technical sections of the New Animal Drug Application for the control of pain associated with bone cancer in dogs. ARK was granted a Minor Use/ Minor Species Drug Designation for ARK-001, a proprietary formulation conta
9/27/16 - Array BioPharma Announces Proposed Public Offering of Common Stock
Array BioPharma today announced that it has commenced an underwritten public offering of $100 million of shares of its common stock. Array BioPharma also intends to grant the underwriters a 30- day option to purchase up to an additional $15 million of shares of its common stock offered in the public offering. All of the shares in the offering are
9/27/16 - Array BioPharma Marches Higher On Phase 3 Columbus Success
Shares of Array Biopharma Inc continue its bull run Tuesday, climbing more than 6 percent after surging 81 percent Monday on the heels of its positive late-stage skin cancer trial results. "With BINI under FDA review& BINI/ ENCO filings in 2017, ARRY would potentially have two drugs on market for melanoma by early 2018," Yang continued. Yang, who
9/27/16 - Array Biopharma Trading At Highest Levels In Over A Year
Array Biopharma Inc shares are trading higher by $0.30 at $6.89 in Tuesday's session. The momentum from Monday's session, rallying from $3.65 to $6.6, 1 has carried over into today's session. The issue hasn't closed above $7 since April 24, 2015, when it ended the session at $7.19.
9/27/16 - ARRY Hits COLUMBUS Goals, KITE Flies After-hrs, FDA Places Hold On CVM Trial
THOUSAND OAKS- Shares of Array BioPharma Inc. jumped more than 81% on Monday, following positive top-line results from Part 1 of the phase III study evaluating the combination of LGX818 and MEK162 compared to Vemurafenib alone in patients with BRAF-mutant advanced, unresectable or metastatic melanoma. The Biologics License Application for Romosozum
9/27/16 - Asterias Biotherapeutics Announces Dosing of First Patient in New SCiSTAR Clinical Trial Cohort Testing AST-OPC1 in an Expanded Cervical Spinal Cord Injury Patient Population
Asterias Biotherapeutics, Inc., a biotechnology company pioneering the field of regenerative medicine, today announced that the first patient with incomplete AIS-B cervical spinal cord injury was successfully dosed with 10 million cells of AST-OPC1 in the SCiSTAR clinical trial at Shepherd Center in Atlanta. The company recently received FDA clea
9/27/16 - Asymmetrex Announces a New Adult Tissue Stem Cell Counting Contract Service to Pharmaceutical and Stem Cell Medical Companies at BioPharm America 2016 in Boston
Asymmetrex, LLC is a Boston- based start-up company whose three years of existence are benchmarked by yearly attendance to BioPharm America conferences in Boston. A signature feature of BioPharm conferences is pre-arranged one-on-one meetings primarily among pharma companies, pharma investors, and pharma suppliers. For the past three years, while..
9/27/16 - Asymmetrex Announces a New Adult Tissue Stem Cell Counting Contract Service to Pharmaceutical and Stem Cell Medical Companies at BioPharm America 2016 in Boston [Moj News Agency (Iran)]
Asymmetrex, LLC is a Boston- based start-up company whose three years of existence are benchmarked by yearly attendance to BioPharm America conferences in Boston. A signature feature of BioPharm conferences is pre-arranged one-on-one meetings primarily among pharma companies, pharma investors, and pharma suppliers. For the past three years, while..
9/27/16 - BeyondSpring Announces First Patient Enrolled in Phase 1b/2 Investigator-Initiated Trial of Plinabulin plus Nivolumab for Non-Small Cell Lung Cancer
BeyondSpring Pharmaceuticals, a clinical stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, announced today that the first patient in the Phase 1 b/2 trial of its lead immuno-oncology asset Plinabulin in combination with Nivolumab, an immune-checkpoint inhibitor, in patients with metastatic.
9/27/16 - BioCryst Closes $23 Million Senior Credit Facility [Cihan News Agency (Turkey)]
-BioCryst Pharmaceuticals, Inc. today announced that the Company has closed a $23 million Senior Credit Facility with Midcap Financial. BioCryst Pharmaceuticals designs, optimizes and develops novel small molecule drugs that block key enzymes involved in rare diseases. MidCap Financial is a middle market-focused, specialty finance firm that provide
9/27/16 - Biosimilars Market Have Major Opportunities, 2020
Biosimilar drugs are used in prevention and treatment of various severe diseases such as cancer, diabetes, autoimmune diseases, heart attacks, rheumatoid arthritis, oncology, growth hormone deficiency, chronic kidney failure, hematological disease and infectious disease.New York City, NY 09/27/2016 Biosimilars or follow-on biologics are...
9/27/16 - Boryung Pharmaceutical to Export Technologies, Products of Kanarb [Khaleej Times (United Arab Emirates)]
Boryung Pharmaceutical Co., one of South Korea`s largest pharmaceutical companies, has signed a contract worth 30 billion won with Mexican pharmaceutical firm Stendhal International at the COEX in Samsung- dong, Seoul, on September 26 to supply its oral hypertension medication, such as Dukarb and Tuvero, to 25 countries, including Mexico.
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2016 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415